HPTN 083-01 is a clinical trial examining whether injectable cabotegravir (CAB) for PrEP (pre-exposure prophylaxis) is safe and acceptable for adolescent males [assigned male at birth –including transgender women (TGW), and gender nonconforming people]. This study will be enrolling about 50 participants at sites in Boston, Chicago, and Memphis.
What will happen during HPTN 083-01?
Participants will move through the study in 3 steps:
- Step 1: Participants will take one CAB pill every day for five weeks
- Step 2: Participants will receive a total of 5 CAB injections over 6 months
- Step 3: Participants will come to the clinic for study visits quarterly and have the option to take Truvada for PrEP for about one year or join another CAB study at the site.